Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9150-9168

  Yan, Hong Hua ^a   Jung, Kyung Hee ^a   Son, Mi Kwon ^a   Fang, Zhenghuan ^a   Kim, Soo Jung ^a   Ryu, Ye Lim ^a   Kim, Juyoung ^a   Kim, Mi Hyun ^b   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

ALK; Apoptosis; C MET; Crizotinib; Pancreatic cancer

Indexed keywords

CASPASE 3; CRIZOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; MITOCHONDRIAL MEMBRANE POTENTIAL; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84910071856     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2363     Document Type: Article

References (35)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362(17):1605-1617.
2. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics. CA Cancer J Clin. 2014; 64(1):9-29.
3. Moore M J, Goldstein D, Hamm J, Figer A, Hecht J R, Gallinger S, Au H J, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K and et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-1966.
4. Van Cutsem E, Vervenne W L, Bennouna J, HumbletY, Gill S, Van Laethem J L, Verslype C, Scheithauer W, ShangA, Cosaert J and Moore M J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009; 27(13):2231-2237.
5. McGinn C J, Zalupski M M, Shureiqi I, RobertsonJM, Eckhauser F E, Smith D C, Brown D, Hejna G, Strawderman M, Normolle D and Lawrence T S. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. JClin Oncol. 2001; 19(22):4202-4208.
6. Liu X, Newton R C and Scherle P A. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010; 16(1):37-45.
7. Sierra J R and Tsao M S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011; 3(1 Suppl):S21-35.
8. Di Renzo M F, Poulsom R, Olivero M, Comoglio P M and Lemoine N R. Expression of the c-MET/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 1995; 55(5):1129-1138.
9. Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E and Tanaka M. Overexpression of c-MET in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol. 2006; 12(24):3878-3882.
10. Zhu G H, Huang C, Qiu Z J, Liu J, Zhang Z H, ZhaoN, FengZ Z and Lv X H. Expression and prognostic significance of CD151, c-MET, and integrin alpha3/alpha6 in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2011; 56(4):1090-1098.
11. Ebert M, Yokoyama M, Friess H, Buchler M W and Korc M. Coexpression of the c-MET proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res. 1994; 54(22):5775-5778.
12. Li C, Wu J J, Hynes M, Dosch J, Sarkar B, Welling T H, Pasca di Magliano M and Simeone D M. c-MET is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011; 141(6):2218-2227.
13. Hage C, Rausch V, Giese N, Giese T, Schonsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J and Herr I. The novel c-MET inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis. 2013; 4:e627.
14. Drexler H G, Gignac S M, von Wasielewski R, Werner M and Dirks W G. Pathobiology of NPM-ALKand variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000; 14(9):1533-1559.
15. Bilsland J G, Wheeldon A, Mead A, Znamenskiy P, AlmondS, Waters K A, Thakur M, Beaumont V, BonnertTP, Heavens R, Whiting P, McAllister G and Munoz-Sanjuan I. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology. 2008; 33(3):685-700.
16. Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013; 68(1):68-94.
17. Chiarle R, Voena C, Ambrogio C, Piva R and InghiramiG. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008; 8(1):11-23.
18. Mosse Y P, Wood A and Maris J M. Inhibition of ALKsignaling for cancer therapy. Clin Cancer Res. 2009; 15(18):5609-5614.
19. Kruczynski A, Delsol G, Laurent C, Brousset P and LamantL. Anaplastic lymphoma kinase as a therapeutictarget. Expert Opin Ther Targets. 2012; 16(11):1127-1138.
20. Schettino C, Bareschino M A, Sacco P C, Maione P, RossiA, Casaluce F, Sgambato A and Gridelli C. New molecular targets in the treatment of NSCLC. Curr Pharm Des. 2013; 19(30):5333-5343.
21. Ou S H. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011; 5:471-485.
22. Zillhardt M, Christensen J G and Lengyel E. An orally available small-molecule inhibitor of c-MET, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010; 12(1):1-10.
23. Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell R J, Lagerweij T, Van Tellingen O, CampaniD, Fuchs D, Verheul H M, Schuurhuis G J, Boggi U, PetersGJ, Wurdinger T and Giovannetti E. Crizotinib inhibits metabolic inactivation of gemcitabine in c-MET-driven pancreatic carcinoma. Cancer Res. 2013; 73(22):6745-6756.
24. Zou H Y, Li Q, Lee J H, Arango M E, McDonnell S R, Yamazaki S, Koudriakova T B, Alton G, Cui J J, KungPP, Nambu M D, Los G, Bender S L, Mroczkowski B and Christensen J G. An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67(9): 4408-4417.
25. Ardini E, Magnaghi P, Orsini P, Galvani A and Menichincheri M. Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett. 2010; 299(2):81-94.
26. Conroy T, Desseigne F, Ychou M, Bouche O, GuimbaudR, Becouarn Y, Adenis A, Raoul J L, Gourgou-BourgadeS, dela Fouchardiere C, Bennouna J, Bachet J B, Khemissa-Akouz F and et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-1825.
27. Grande E, Bolos M V and Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther. 2011; 10(4):569-579.
28. Rodig S J and Shapiro G I. Crizotinib, a small-molecule dual inhibitor of the c-MET and ALKreceptor tyrosine kinases. Curr Opin Investig Drugs. 2010; 11(12):1477-1490.
29. Okamoto W, Okamoto I, Arao T, Kuwata K, HatashitaE, Yamaguchi H, Sakai K, Yanagihara K, Nishio K and Nakagawa K. Antitumor action of the c-MET tyrosine kinase inhibitor Crizotinib (PF-02341066) in gastric cancer positive for c-MET amplification. Mol Cancer Ther. 2012; 11(7):1557-1564.
30. Tanizaki J, Okamoto I, Okamoto K, Takezawa K, KuwataK, Yamaguchi H and Nakagawa K. c-MET tyrosine kinase inhibitor Crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011; 6(10):1624-1631.
31. Herreros-Villanueva M, Zubia-Olascoaga A and BujandaL. c-MET in pancreatic cancer stem cells: therapeutic implications. World J Gastroenterol. 2012; 18(38): 5321-5323.
32. Hong S W, Jung K H, Lee H S, Son M K, Yan H H, KangNS, Lee J, Hong S S and SB365, Pulsatilla saponin D, targets c-MET and exerts antiangiogenic and antitumor activities. Carcinogenesis. 2013; 34(9): 2156-2169.
33. Szpiro A A, Paciorek C J and Sheppard L. Does more accurate exposure prediction necessarily improve health effect estimates?. Epidemiology. 2011; 22(5):680-685.
34. Seo J H, Jung K H, Son M K, Yan H H, Ryu Y L, KimJ, LeeJ K, Hong S and Hong S S. Anti-cancer effect of HS-345, a new tropomyosin-related kinase A inhibitor, on human pancreatic cancer. Cancer Lett. 2013; 338(2): 271-281.
35. Lee H, Jung K H, Jeong Y, Hong S and Hong S S. HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis. Cancer Lett. 2012; 328(1):152-159.